Modality
ERT
MOA
SHP2i
Target
BCL-2
Pathway
Epigenetic
EoEThymoma
Development Pipeline
Preclinical
May 2020
→ Nov 2025
PreclinicalCurrent
NCT06638526
936 pts·EoE
2021-06→TBD·Not yet recruiting
NCT05877212
1,460 pts·Thymoma
2020-05→2025-11·Completed
2,396 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-035mo agoInterim· Thymoma
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Preclinical
Complet…
Preclinical
Not yet…
Catalysts
Interim
2025-11-03 · 5mo ago
Thymoma
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06638526 | Preclinical | EoE | Not yet recr... | 936 | VA |
| NCT05877212 | Preclinical | Thymoma | Completed | 1460 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Daratuximab | BioMarin | Phase 1 | PRMT5 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 |